Single-Agent Ibrutinib in Relapsed or Refractory Follicular Lymphoma: A Phase 2 Consortium Trial

Key points – Ibrutinib has modest activity in follicular lymphoma with low response rates in rituximab-refractory patients. CARD11 mutations predict for lack of response to ibrutinib.